nodes	percent_of_prediction	percent_of_DWPC	metapath
Ifosfamide—Alkylating Activity—Chlorambucil—testicular cancer	0.548	1	CiPCiCtD
Ifosfamide—germ cell cancer—testicular cancer	0.333	1	CtDrD
Ifosfamide—PTGS1—Etoposide—testicular cancer	0.00891	0.22	CbGbCtD
Ifosfamide—CYP2B6—Cisplatin—testicular cancer	0.00691	0.171	CbGbCtD
Ifosfamide—CYP3A5—Etoposide—testicular cancer	0.00535	0.132	CbGbCtD
Ifosfamide—CYP2C8—Etoposide—testicular cancer	0.00514	0.127	CbGbCtD
Ifosfamide—CYP2B6—Doxorubicin—testicular cancer	0.00463	0.115	CbGbCtD
Ifosfamide—CYP2C9—Cisplatin—testicular cancer	0.00365	0.0903	CbGbCtD
Ifosfamide—CYP3A4—Vinblastine—testicular cancer	0.00231	0.0573	CbGbCtD
Ifosfamide—CYP3A4—Etoposide—testicular cancer	0.00208	0.0516	CbGbCtD
Ifosfamide—CYP3A4—Doxorubicin—testicular cancer	0.00142	0.0352	CbGbCtD
Ifosfamide—Body temperature increased—Cisplatin—testicular cancer	2.7e-05	0.000342	CcSEcCtD
Ifosfamide—Fatigue—Etoposide—testicular cancer	2.7e-05	0.000342	CcSEcCtD
Ifosfamide—Neuropathy peripheral—Epirubicin—testicular cancer	2.69e-05	0.000342	CcSEcCtD
Ifosfamide—Stomatitis—Epirubicin—testicular cancer	2.68e-05	0.00034	CcSEcCtD
Ifosfamide—Pain—Etoposide—testicular cancer	2.67e-05	0.000339	CcSEcCtD
Ifosfamide—Constipation—Etoposide—testicular cancer	2.67e-05	0.000339	CcSEcCtD
Ifosfamide—Conjunctivitis—Epirubicin—testicular cancer	2.67e-05	0.000339	CcSEcCtD
Ifosfamide—Dysuria—Doxorubicin—testicular cancer	2.67e-05	0.000339	CcSEcCtD
Ifosfamide—Haemoglobin—Methotrexate—testicular cancer	2.65e-05	0.000336	CcSEcCtD
Ifosfamide—Haemorrhage—Methotrexate—testicular cancer	2.64e-05	0.000335	CcSEcCtD
Ifosfamide—Hepatitis—Methotrexate—testicular cancer	2.64e-05	0.000335	CcSEcCtD
Ifosfamide—Pollakiuria—Doxorubicin—testicular cancer	2.63e-05	0.000334	CcSEcCtD
Ifosfamide—Haematuria—Epirubicin—testicular cancer	2.62e-05	0.000333	CcSEcCtD
Ifosfamide—Urinary tract disorder—Methotrexate—testicular cancer	2.6e-05	0.00033	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Epirubicin—testicular cancer	2.6e-05	0.00033	CcSEcCtD
Ifosfamide—Urethral disorder—Methotrexate—testicular cancer	2.58e-05	0.000328	CcSEcCtD
Ifosfamide—Feeling abnormal—Etoposide—testicular cancer	2.58e-05	0.000327	CcSEcCtD
Ifosfamide—Hyperglycaemia—Doxorubicin—testicular cancer	2.57e-05	0.000327	CcSEcCtD
Ifosfamide—Nausea—Dactinomycin—testicular cancer	2.57e-05	0.000326	CcSEcCtD
Ifosfamide—Agranulocytosis—Epirubicin—testicular cancer	2.56e-05	0.000326	CcSEcCtD
Ifosfamide—Pneumonia—Doxorubicin—testicular cancer	2.56e-05	0.000325	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Etoposide—testicular cancer	2.56e-05	0.000325	CcSEcCtD
Ifosfamide—Infestation NOS—Doxorubicin—testicular cancer	2.54e-05	0.000323	CcSEcCtD
Ifosfamide—Infestation—Doxorubicin—testicular cancer	2.54e-05	0.000323	CcSEcCtD
Ifosfamide—Visual impairment—Methotrexate—testicular cancer	2.54e-05	0.000322	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	2.52e-05	0.00032	CcSEcCtD
Ifosfamide—Hypersensitivity—Cisplatin—testicular cancer	2.51e-05	0.000319	CcSEcCtD
Ifosfamide—Bradycardia—Epirubicin—testicular cancer	2.51e-05	0.000319	CcSEcCtD
Ifosfamide—Renal failure—Doxorubicin—testicular cancer	2.5e-05	0.000317	CcSEcCtD
Ifosfamide—Erythema multiforme—Methotrexate—testicular cancer	2.49e-05	0.000316	CcSEcCtD
Ifosfamide—Neuropathy peripheral—Doxorubicin—testicular cancer	2.49e-05	0.000316	CcSEcCtD
Ifosfamide—Urticaria—Etoposide—testicular cancer	2.48e-05	0.000315	CcSEcCtD
Ifosfamide—Haemoglobin—Epirubicin—testicular cancer	2.48e-05	0.000315	CcSEcCtD
Ifosfamide—Stomatitis—Doxorubicin—testicular cancer	2.48e-05	0.000315	CcSEcCtD
Ifosfamide—Body temperature increased—Etoposide—testicular cancer	2.47e-05	0.000314	CcSEcCtD
Ifosfamide—Abdominal pain—Etoposide—testicular cancer	2.47e-05	0.000314	CcSEcCtD
Ifosfamide—Conjunctivitis—Doxorubicin—testicular cancer	2.47e-05	0.000314	CcSEcCtD
Ifosfamide—Haemorrhage—Epirubicin—testicular cancer	2.47e-05	0.000313	CcSEcCtD
Ifosfamide—Hepatitis—Epirubicin—testicular cancer	2.47e-05	0.000313	CcSEcCtD
Ifosfamide—Eye disorder—Methotrexate—testicular cancer	2.46e-05	0.000313	CcSEcCtD
Ifosfamide—Tinnitus—Methotrexate—testicular cancer	2.46e-05	0.000312	CcSEcCtD
Ifosfamide—Asthenia—Cisplatin—testicular cancer	2.45e-05	0.000311	CcSEcCtD
Ifosfamide—Cardiac disorder—Methotrexate—testicular cancer	2.45e-05	0.000311	CcSEcCtD
Ifosfamide—Urinary tract disorder—Epirubicin—testicular cancer	2.44e-05	0.000309	CcSEcCtD
Ifosfamide—Haematuria—Doxorubicin—testicular cancer	2.42e-05	0.000308	CcSEcCtD
Ifosfamide—Connective tissue disorder—Epirubicin—testicular cancer	2.42e-05	0.000308	CcSEcCtD
Ifosfamide—Urethral disorder—Epirubicin—testicular cancer	2.42e-05	0.000307	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Doxorubicin—testicular cancer	2.41e-05	0.000305	CcSEcCtD
Ifosfamide—Angiopathy—Methotrexate—testicular cancer	2.39e-05	0.000304	CcSEcCtD
Ifosfamide—Immune system disorder—Methotrexate—testicular cancer	2.38e-05	0.000302	CcSEcCtD
Ifosfamide—Visual impairment—Epirubicin—testicular cancer	2.38e-05	0.000302	CcSEcCtD
Ifosfamide—Mediastinal disorder—Methotrexate—testicular cancer	2.38e-05	0.000302	CcSEcCtD
Ifosfamide—Agranulocytosis—Doxorubicin—testicular cancer	2.37e-05	0.000301	CcSEcCtD
Ifosfamide—Chills—Methotrexate—testicular cancer	2.37e-05	0.0003	CcSEcCtD
Ifosfamide—Diarrhoea—Cisplatin—testicular cancer	2.34e-05	0.000296	CcSEcCtD
Ifosfamide—Erythema multiforme—Epirubicin—testicular cancer	2.33e-05	0.000296	CcSEcCtD
Ifosfamide—Alopecia—Methotrexate—testicular cancer	2.33e-05	0.000296	CcSEcCtD
Ifosfamide—Bradycardia—Doxorubicin—testicular cancer	2.32e-05	0.000295	CcSEcCtD
Ifosfamide—Mental disorder—Methotrexate—testicular cancer	2.31e-05	0.000293	CcSEcCtD
Ifosfamide—Eye disorder—Epirubicin—testicular cancer	2.31e-05	0.000293	CcSEcCtD
Ifosfamide—Hypersensitivity—Etoposide—testicular cancer	2.3e-05	0.000292	CcSEcCtD
Ifosfamide—Tinnitus—Epirubicin—testicular cancer	2.3e-05	0.000292	CcSEcCtD
Ifosfamide—Erythema—Methotrexate—testicular cancer	2.3e-05	0.000291	CcSEcCtD
Ifosfamide—Malnutrition—Methotrexate—testicular cancer	2.3e-05	0.000291	CcSEcCtD
Ifosfamide—Haemoglobin—Doxorubicin—testicular cancer	2.29e-05	0.000291	CcSEcCtD
Ifosfamide—Cardiac disorder—Epirubicin—testicular cancer	2.29e-05	0.000291	CcSEcCtD
Ifosfamide—Flushing—Epirubicin—testicular cancer	2.29e-05	0.000291	CcSEcCtD
Ifosfamide—Hepatitis—Doxorubicin—testicular cancer	2.28e-05	0.00029	CcSEcCtD
Ifosfamide—Haemorrhage—Doxorubicin—testicular cancer	2.28e-05	0.00029	CcSEcCtD
Ifosfamide—Urinary tract disorder—Doxorubicin—testicular cancer	2.25e-05	0.000286	CcSEcCtD
Ifosfamide—Asthenia—Etoposide—testicular cancer	2.24e-05	0.000285	CcSEcCtD
Ifosfamide—Connective tissue disorder—Doxorubicin—testicular cancer	2.24e-05	0.000285	CcSEcCtD
Ifosfamide—Angiopathy—Epirubicin—testicular cancer	2.24e-05	0.000284	CcSEcCtD
Ifosfamide—Urethral disorder—Doxorubicin—testicular cancer	2.24e-05	0.000284	CcSEcCtD
Ifosfamide—Immune system disorder—Epirubicin—testicular cancer	2.23e-05	0.000283	CcSEcCtD
Ifosfamide—Mediastinal disorder—Epirubicin—testicular cancer	2.22e-05	0.000282	CcSEcCtD
Ifosfamide—Chills—Epirubicin—testicular cancer	2.21e-05	0.000281	CcSEcCtD
Ifosfamide—Pruritus—Etoposide—testicular cancer	2.21e-05	0.000281	CcSEcCtD
Ifosfamide—Arrhythmia—Epirubicin—testicular cancer	2.2e-05	0.00028	CcSEcCtD
Ifosfamide—Visual impairment—Doxorubicin—testicular cancer	2.2e-05	0.000279	CcSEcCtD
Ifosfamide—Alopecia—Epirubicin—testicular cancer	2.18e-05	0.000277	CcSEcCtD
Ifosfamide—Vomiting—Cisplatin—testicular cancer	2.17e-05	0.000275	CcSEcCtD
Ifosfamide—Vision blurred—Methotrexate—testicular cancer	2.16e-05	0.000275	CcSEcCtD
Ifosfamide—Mental disorder—Epirubicin—testicular cancer	2.16e-05	0.000274	CcSEcCtD
Ifosfamide—Erythema multiforme—Doxorubicin—testicular cancer	2.16e-05	0.000274	CcSEcCtD
Ifosfamide—Rash—Cisplatin—testicular cancer	2.15e-05	0.000273	CcSEcCtD
Ifosfamide—Dermatitis—Cisplatin—testicular cancer	2.15e-05	0.000273	CcSEcCtD
Ifosfamide—Erythema—Epirubicin—testicular cancer	2.15e-05	0.000273	CcSEcCtD
Ifosfamide—Malnutrition—Epirubicin—testicular cancer	2.15e-05	0.000273	CcSEcCtD
Ifosfamide—Diarrhoea—Etoposide—testicular cancer	2.14e-05	0.000272	CcSEcCtD
Ifosfamide—Eye disorder—Doxorubicin—testicular cancer	2.13e-05	0.000271	CcSEcCtD
Ifosfamide—Ill-defined disorder—Methotrexate—testicular cancer	2.13e-05	0.00027	CcSEcCtD
Ifosfamide—Tinnitus—Doxorubicin—testicular cancer	2.13e-05	0.00027	CcSEcCtD
Ifosfamide—Anaemia—Methotrexate—testicular cancer	2.12e-05	0.000269	CcSEcCtD
Ifosfamide—Cardiac disorder—Doxorubicin—testicular cancer	2.12e-05	0.000269	CcSEcCtD
Ifosfamide—Flushing—Doxorubicin—testicular cancer	2.12e-05	0.000269	CcSEcCtD
Ifosfamide—Angiopathy—Doxorubicin—testicular cancer	2.07e-05	0.000263	CcSEcCtD
Ifosfamide—Malaise—Methotrexate—testicular cancer	2.07e-05	0.000263	CcSEcCtD
Ifosfamide—Dizziness—Etoposide—testicular cancer	2.07e-05	0.000262	CcSEcCtD
Ifosfamide—Immune system disorder—Doxorubicin—testicular cancer	2.06e-05	0.000262	CcSEcCtD
Ifosfamide—Vertigo—Methotrexate—testicular cancer	2.06e-05	0.000262	CcSEcCtD
Ifosfamide—Mediastinal disorder—Doxorubicin—testicular cancer	2.06e-05	0.000261	CcSEcCtD
Ifosfamide—Leukopenia—Methotrexate—testicular cancer	2.05e-05	0.000261	CcSEcCtD
Ifosfamide—Chills—Doxorubicin—testicular cancer	2.05e-05	0.00026	CcSEcCtD
Ifosfamide—Arrhythmia—Doxorubicin—testicular cancer	2.04e-05	0.000259	CcSEcCtD
Ifosfamide—Nausea—Cisplatin—testicular cancer	2.03e-05	0.000257	CcSEcCtD
Ifosfamide—Vision blurred—Epirubicin—testicular cancer	2.02e-05	0.000257	CcSEcCtD
Ifosfamide—Alopecia—Doxorubicin—testicular cancer	2.02e-05	0.000256	CcSEcCtD
Ifosfamide—Cough—Methotrexate—testicular cancer	2e-05	0.000254	CcSEcCtD
Ifosfamide—Mental disorder—Doxorubicin—testicular cancer	2e-05	0.000254	CcSEcCtD
Ifosfamide—Ill-defined disorder—Epirubicin—testicular cancer	1.99e-05	0.000253	CcSEcCtD
Ifosfamide—Convulsion—Methotrexate—testicular cancer	1.99e-05	0.000252	CcSEcCtD
Ifosfamide—Vomiting—Etoposide—testicular cancer	1.99e-05	0.000252	CcSEcCtD
Ifosfamide—Malnutrition—Doxorubicin—testicular cancer	1.99e-05	0.000252	CcSEcCtD
Ifosfamide—Erythema—Doxorubicin—testicular cancer	1.99e-05	0.000252	CcSEcCtD
Ifosfamide—Anaemia—Epirubicin—testicular cancer	1.99e-05	0.000252	CcSEcCtD
Ifosfamide—Agitation—Epirubicin—testicular cancer	1.97e-05	0.000251	CcSEcCtD
Ifosfamide—Rash—Etoposide—testicular cancer	1.97e-05	0.00025	CcSEcCtD
Ifosfamide—Dermatitis—Etoposide—testicular cancer	1.97e-05	0.00025	CcSEcCtD
Ifosfamide—Arthralgia—Methotrexate—testicular cancer	1.95e-05	0.000248	CcSEcCtD
Ifosfamide—Chest pain—Methotrexate—testicular cancer	1.95e-05	0.000248	CcSEcCtD
Ifosfamide—Myalgia—Methotrexate—testicular cancer	1.95e-05	0.000248	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	1.94e-05	0.000246	CcSEcCtD
Ifosfamide—Malaise—Epirubicin—testicular cancer	1.94e-05	0.000246	CcSEcCtD
Ifosfamide—Discomfort—Methotrexate—testicular cancer	1.93e-05	0.000245	CcSEcCtD
Ifosfamide—Vertigo—Epirubicin—testicular cancer	1.93e-05	0.000245	CcSEcCtD
Ifosfamide—Leukopenia—Epirubicin—testicular cancer	1.92e-05	0.000244	CcSEcCtD
Ifosfamide—Palpitations—Epirubicin—testicular cancer	1.9e-05	0.000241	CcSEcCtD
Ifosfamide—Confusional state—Methotrexate—testicular cancer	1.89e-05	0.00024	CcSEcCtD
Ifosfamide—Cough—Epirubicin—testicular cancer	1.87e-05	0.000238	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methotrexate—testicular cancer	1.87e-05	0.000238	CcSEcCtD
Ifosfamide—Vision blurred—Doxorubicin—testicular cancer	1.87e-05	0.000238	CcSEcCtD
Ifosfamide—Convulsion—Epirubicin—testicular cancer	1.86e-05	0.000236	CcSEcCtD
Ifosfamide—Infection—Methotrexate—testicular cancer	1.86e-05	0.000236	CcSEcCtD
Ifosfamide—Nausea—Etoposide—testicular cancer	1.86e-05	0.000236	CcSEcCtD
Ifosfamide—Hypertension—Epirubicin—testicular cancer	1.85e-05	0.000235	CcSEcCtD
Ifosfamide—Ill-defined disorder—Doxorubicin—testicular cancer	1.84e-05	0.000234	CcSEcCtD
Ifosfamide—Nervous system disorder—Methotrexate—testicular cancer	1.84e-05	0.000233	CcSEcCtD
Ifosfamide—Anaemia—Doxorubicin—testicular cancer	1.84e-05	0.000233	CcSEcCtD
Ifosfamide—Thrombocytopenia—Methotrexate—testicular cancer	1.83e-05	0.000233	CcSEcCtD
Ifosfamide—Myalgia—Epirubicin—testicular cancer	1.83e-05	0.000232	CcSEcCtD
Ifosfamide—Chest pain—Epirubicin—testicular cancer	1.83e-05	0.000232	CcSEcCtD
Ifosfamide—Arthralgia—Epirubicin—testicular cancer	1.83e-05	0.000232	CcSEcCtD
Ifosfamide—Agitation—Doxorubicin—testicular cancer	1.83e-05	0.000232	CcSEcCtD
Ifosfamide—Skin disorder—Methotrexate—testicular cancer	1.82e-05	0.000231	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	1.82e-05	0.00023	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methotrexate—testicular cancer	1.81e-05	0.00023	CcSEcCtD
Ifosfamide—Discomfort—Epirubicin—testicular cancer	1.81e-05	0.000229	CcSEcCtD
Ifosfamide—Malaise—Doxorubicin—testicular cancer	1.79e-05	0.000227	CcSEcCtD
Ifosfamide—Vertigo—Doxorubicin—testicular cancer	1.79e-05	0.000227	CcSEcCtD
Ifosfamide—Anorexia—Methotrexate—testicular cancer	1.79e-05	0.000227	CcSEcCtD
Ifosfamide—Leukopenia—Doxorubicin—testicular cancer	1.78e-05	0.000226	CcSEcCtD
Ifosfamide—Confusional state—Epirubicin—testicular cancer	1.77e-05	0.000224	CcSEcCtD
Ifosfamide—Palpitations—Doxorubicin—testicular cancer	1.76e-05	0.000223	CcSEcCtD
Ifosfamide—Anaphylactic shock—Epirubicin—testicular cancer	1.75e-05	0.000222	CcSEcCtD
Ifosfamide—Oedema—Epirubicin—testicular cancer	1.75e-05	0.000222	CcSEcCtD
Ifosfamide—Hypotension—Methotrexate—testicular cancer	1.75e-05	0.000222	CcSEcCtD
Ifosfamide—Infection—Epirubicin—testicular cancer	1.74e-05	0.000221	CcSEcCtD
Ifosfamide—Cough—Doxorubicin—testicular cancer	1.73e-05	0.00022	CcSEcCtD
Ifosfamide—Convulsion—Doxorubicin—testicular cancer	1.72e-05	0.000219	CcSEcCtD
Ifosfamide—Nervous system disorder—Epirubicin—testicular cancer	1.72e-05	0.000218	CcSEcCtD
Ifosfamide—Thrombocytopenia—Epirubicin—testicular cancer	1.72e-05	0.000218	CcSEcCtD
Ifosfamide—Hypertension—Doxorubicin—testicular cancer	1.72e-05	0.000218	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.71e-05	0.000217	CcSEcCtD
Ifosfamide—Skin disorder—Epirubicin—testicular cancer	1.7e-05	0.000216	CcSEcCtD
Ifosfamide—Hyperhidrosis—Epirubicin—testicular cancer	1.69e-05	0.000215	CcSEcCtD
Ifosfamide—Myalgia—Doxorubicin—testicular cancer	1.69e-05	0.000215	CcSEcCtD
Ifosfamide—Arthralgia—Doxorubicin—testicular cancer	1.69e-05	0.000215	CcSEcCtD
Ifosfamide—Chest pain—Doxorubicin—testicular cancer	1.69e-05	0.000215	CcSEcCtD
Ifosfamide—Paraesthesia—Methotrexate—testicular cancer	1.68e-05	0.000213	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.68e-05	0.000213	CcSEcCtD
Ifosfamide—Discomfort—Doxorubicin—testicular cancer	1.67e-05	0.000212	CcSEcCtD
Ifosfamide—Anorexia—Epirubicin—testicular cancer	1.67e-05	0.000212	CcSEcCtD
Ifosfamide—Dyspnoea—Methotrexate—testicular cancer	1.67e-05	0.000212	CcSEcCtD
Ifosfamide—Somnolence—Methotrexate—testicular cancer	1.67e-05	0.000211	CcSEcCtD
Ifosfamide—Hypotension—Epirubicin—testicular cancer	1.64e-05	0.000208	CcSEcCtD
Ifosfamide—Confusional state—Doxorubicin—testicular cancer	1.64e-05	0.000208	CcSEcCtD
Ifosfamide—Decreased appetite—Methotrexate—testicular cancer	1.63e-05	0.000207	CcSEcCtD
Ifosfamide—Oedema—Doxorubicin—testicular cancer	1.62e-05	0.000206	CcSEcCtD
Ifosfamide—Anaphylactic shock—Doxorubicin—testicular cancer	1.62e-05	0.000206	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Methotrexate—testicular cancer	1.62e-05	0.000205	CcSEcCtD
Ifosfamide—Fatigue—Methotrexate—testicular cancer	1.61e-05	0.000205	CcSEcCtD
Ifosfamide—Infection—Doxorubicin—testicular cancer	1.61e-05	0.000205	CcSEcCtD
Ifosfamide—Pain—Methotrexate—testicular cancer	1.6e-05	0.000203	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Epirubicin—testicular cancer	1.6e-05	0.000203	CcSEcCtD
Ifosfamide—Nervous system disorder—Doxorubicin—testicular cancer	1.59e-05	0.000202	CcSEcCtD
Ifosfamide—Thrombocytopenia—Doxorubicin—testicular cancer	1.59e-05	0.000202	CcSEcCtD
Ifosfamide—Skin disorder—Doxorubicin—testicular cancer	1.58e-05	0.0002	CcSEcCtD
Ifosfamide—Paraesthesia—Epirubicin—testicular cancer	1.57e-05	0.0002	CcSEcCtD
Ifosfamide—Hyperhidrosis—Doxorubicin—testicular cancer	1.57e-05	0.000199	CcSEcCtD
Ifosfamide—Dyspnoea—Epirubicin—testicular cancer	1.56e-05	0.000198	CcSEcCtD
Ifosfamide—Somnolence—Epirubicin—testicular cancer	1.56e-05	0.000198	CcSEcCtD
Ifosfamide—Anorexia—Doxorubicin—testicular cancer	1.55e-05	0.000196	CcSEcCtD
Ifosfamide—Feeling abnormal—Methotrexate—testicular cancer	1.54e-05	0.000196	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methotrexate—testicular cancer	1.53e-05	0.000194	CcSEcCtD
Ifosfamide—Decreased appetite—Epirubicin—testicular cancer	1.52e-05	0.000193	CcSEcCtD
Ifosfamide—Hypotension—Doxorubicin—testicular cancer	1.52e-05	0.000192	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Epirubicin—testicular cancer	1.51e-05	0.000192	CcSEcCtD
Ifosfamide—Fatigue—Epirubicin—testicular cancer	1.51e-05	0.000192	CcSEcCtD
Ifosfamide—Constipation—Epirubicin—testicular cancer	1.5e-05	0.00019	CcSEcCtD
Ifosfamide—Pain—Epirubicin—testicular cancer	1.5e-05	0.00019	CcSEcCtD
Ifosfamide—Urticaria—Methotrexate—testicular cancer	1.49e-05	0.000189	CcSEcCtD
Ifosfamide—Abdominal pain—Methotrexate—testicular cancer	1.48e-05	0.000188	CcSEcCtD
Ifosfamide—Body temperature increased—Methotrexate—testicular cancer	1.48e-05	0.000188	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	1.48e-05	0.000188	CcSEcCtD
Ifosfamide—Paraesthesia—Doxorubicin—testicular cancer	1.46e-05	0.000185	CcSEcCtD
Ifosfamide—Dyspnoea—Doxorubicin—testicular cancer	1.45e-05	0.000184	CcSEcCtD
Ifosfamide—Feeling abnormal—Epirubicin—testicular cancer	1.44e-05	0.000183	CcSEcCtD
Ifosfamide—Somnolence—Doxorubicin—testicular cancer	1.44e-05	0.000183	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Epirubicin—testicular cancer	1.43e-05	0.000182	CcSEcCtD
Ifosfamide—Decreased appetite—Doxorubicin—testicular cancer	1.41e-05	0.000179	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.4e-05	0.000178	CcSEcCtD
Ifosfamide—Fatigue—Doxorubicin—testicular cancer	1.4e-05	0.000177	CcSEcCtD
Ifosfamide—Urticaria—Epirubicin—testicular cancer	1.39e-05	0.000177	CcSEcCtD
Ifosfamide—Pain—Doxorubicin—testicular cancer	1.39e-05	0.000176	CcSEcCtD
Ifosfamide—Constipation—Doxorubicin—testicular cancer	1.39e-05	0.000176	CcSEcCtD
Ifosfamide—Abdominal pain—Epirubicin—testicular cancer	1.39e-05	0.000176	CcSEcCtD
Ifosfamide—Body temperature increased—Epirubicin—testicular cancer	1.39e-05	0.000176	CcSEcCtD
Ifosfamide—Hypersensitivity—Methotrexate—testicular cancer	1.38e-05	0.000175	CcSEcCtD
Ifosfamide—Asthenia—Methotrexate—testicular cancer	1.34e-05	0.000171	CcSEcCtD
Ifosfamide—Feeling abnormal—Doxorubicin—testicular cancer	1.34e-05	0.00017	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Doxorubicin—testicular cancer	1.33e-05	0.000168	CcSEcCtD
Ifosfamide—Pruritus—Methotrexate—testicular cancer	1.33e-05	0.000168	CcSEcCtD
Ifosfamide—Hypersensitivity—Epirubicin—testicular cancer	1.29e-05	0.000164	CcSEcCtD
Ifosfamide—Urticaria—Doxorubicin—testicular cancer	1.29e-05	0.000164	CcSEcCtD
Ifosfamide—Abdominal pain—Doxorubicin—testicular cancer	1.28e-05	0.000163	CcSEcCtD
Ifosfamide—Body temperature increased—Doxorubicin—testicular cancer	1.28e-05	0.000163	CcSEcCtD
Ifosfamide—Diarrhoea—Methotrexate—testicular cancer	1.28e-05	0.000163	CcSEcCtD
Ifosfamide—Asthenia—Epirubicin—testicular cancer	1.26e-05	0.00016	CcSEcCtD
Ifosfamide—Pruritus—Epirubicin—testicular cancer	1.24e-05	0.000157	CcSEcCtD
Ifosfamide—Dizziness—Methotrexate—testicular cancer	1.24e-05	0.000157	CcSEcCtD
Ifosfamide—Diarrhoea—Epirubicin—testicular cancer	1.2e-05	0.000152	CcSEcCtD
Ifosfamide—Hypersensitivity—Doxorubicin—testicular cancer	1.19e-05	0.000152	CcSEcCtD
Ifosfamide—Vomiting—Methotrexate—testicular cancer	1.19e-05	0.000151	CcSEcCtD
Ifosfamide—Rash—Methotrexate—testicular cancer	1.18e-05	0.00015	CcSEcCtD
Ifosfamide—Dermatitis—Methotrexate—testicular cancer	1.18e-05	0.00015	CcSEcCtD
Ifosfamide—Asthenia—Doxorubicin—testicular cancer	1.16e-05	0.000148	CcSEcCtD
Ifosfamide—Dizziness—Epirubicin—testicular cancer	1.16e-05	0.000147	CcSEcCtD
Ifosfamide—Pruritus—Doxorubicin—testicular cancer	1.15e-05	0.000146	CcSEcCtD
Ifosfamide—Vomiting—Epirubicin—testicular cancer	1.11e-05	0.000141	CcSEcCtD
Ifosfamide—Nausea—Methotrexate—testicular cancer	1.11e-05	0.000141	CcSEcCtD
Ifosfamide—Diarrhoea—Doxorubicin—testicular cancer	1.11e-05	0.000141	CcSEcCtD
Ifosfamide—Rash—Epirubicin—testicular cancer	1.11e-05	0.00014	CcSEcCtD
Ifosfamide—Dermatitis—Epirubicin—testicular cancer	1.1e-05	0.00014	CcSEcCtD
Ifosfamide—Dizziness—Doxorubicin—testicular cancer	1.07e-05	0.000136	CcSEcCtD
Ifosfamide—Nausea—Epirubicin—testicular cancer	1.04e-05	0.000132	CcSEcCtD
Ifosfamide—Vomiting—Doxorubicin—testicular cancer	1.03e-05	0.000131	CcSEcCtD
Ifosfamide—Rash—Doxorubicin—testicular cancer	1.02e-05	0.00013	CcSEcCtD
Ifosfamide—Dermatitis—Doxorubicin—testicular cancer	1.02e-05	0.00013	CcSEcCtD
Ifosfamide—Nausea—Doxorubicin—testicular cancer	9.63e-06	0.000122	CcSEcCtD
